

Journal Pre-proofs

New Antibacterial Cadiolide Analogues active Against Antibiotic Bacterial Resistant Strains

Sarra Bekri, Florie Desriac, Magalie Barreau, Thomas Clamens, Thibault Gallavardin, Patricia Le Nahenec-Martel, Julien Vieillard, Yazid Datoussaid, Nouredine Choukchou-Braham, Olivier Lesouhaitier, Xavier Franck, Stéphane Leleu

PII: S0960-894X(20)30691-0
DOI: <https://doi.org/10.1016/j.bmcl.2020.127580>
Reference: BMCL 127580

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 22 July 2020
Revised Date: 14 September 2020
Accepted Date: 22 September 2020

Please cite this article as: Bekri, S., Desriac, F., Barreau, M., Clamens, T., Gallavardin, T., Nahenec-Martel, P.L., Vieillard, J., Datoussaid, Y., Choukchou-Braham, N., Lesouhaitier, O., Franck, X., Leleu, S., New Antibacterial Cadiolide Analogues active Against Antibiotic Bacterial Resistant Strains, *Bioorganic & Medicinal Chemistry Letters* (2020), doi: <https://doi.org/10.1016/j.bmcl.2020.127580>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Ltd.




Graphical Abstract

To create your abstract, type over the instructions in the template box below.
 Fonts or abstract dimensions should not be changed or altered.

New Antibacterial Cadiolide Analogues Active Against Antibiotic Resistant Bacterial Strains

Leave this area blank for abstract info.

Sarra Bekri, Florie Desriac, Magalie Barreau, Thomas Clamens, Thibault Gallavardin, Patricia Le Nahenec-Martel, Julien Vieillard, Yazid Datoussaid, Noureddine Choukhou-Braham, Olivier Lesouhaitier, Xavier Franck and Stéphane Leleu*



One-pot multicomponent synthesis of 12 new cadiolide analogues
 3 promising active analogues with MIC between 2 and 16 $\mu\text{g}\cdot\text{mL}^{-1}$
 non cytotoxicity against keratocyte cells

Journal Pre-proofs



New Antibacterial Cadiolide Analogues active Against Antibiotic Bacterial Resistant Strains

Sarra Bekri^{a,b}, Florie Desriac^{c,d}, Magalie Barreau^c, Thomas Clamens^c, Thibault Gallavardin^a, Patricia Le Nahenec-Martel^a, Julien Vieillard^a, Yazid Datoussaid^b, Nouredine Choukchou-Braham^b, Olivier Lesouhaitier^c, Xavier Franck^a and Stéphane Leleu^{a,*}

^a Normandie Univ, CNRS, INSA Rouen, UNIROUEN, COBRA (UMR 6014 and FR 3038), 76000 Rouen, France

^b Laboratoire de Catalyse et Synthèse en Chimie Organique, Faculté des Sciences, Université Abou-Bekr Belkaid, BP 119, 13000 Tlemcen, Algeria.

^c Laboratoire de Microbiologie Signaux et Microenvironnement (LMSM) EA 4312, Normandie Université, UNIROUEN, Evreux, France

^d Faculty of Health: Medicine, Dentistry and Human Sciences. University of Plymouth, Plymouth, United-Kingdom.

ARTICLE INFO

Article history:

Received

Revised

Accepted

Available online

Keywords:

Cadiolide analogues

Antibacterial

Antibiotic-resistance

Natural Products

ABSTRACT

The synthesis of new cadiolide analogues was carried out using a one-pot multi component synthesis. The antibacterial activity of these molecules was evaluated on standard and antibiotic resistant bacterial strains chosen for their involvement in human health or in food-born poisoning. Four molecules have shown good activities with MICs of 2 $\mu\text{g}/\text{mL}^{-1}$. The introduction of an indole group or the conversion of the lactone into lactam have highlighted two new families of molecules with promising antibacterial activity. In addition, most of these active molecules are devoid of cytotoxic activity against keratinocyte cells.

2009 Elsevier Ltd. All rights reserved.

* Stéphane Leleu. Tel.: +33-(0)2-35-52-24-67; fax: +33-(0)2-35-52-29-59; e-mail: stephane.leleu@univ-rouen.fr.

significantly increased life expectancy. However, their intensive and repeated use, or even misuse, for both human and animal treatment in the hospital or agricultural environments has contributed to the development of resistant strains. The fight against this phenomenon is becoming a major public health issue. For this reason, numerous research groups and pharmaceutical industries have focused their work on the design and the discovery of new antibacterial compounds.

The most critical antibiotic-resistant strains requiring urgent new drug discovery have been recently reassessed by The World Health Organization (WHO).¹ Among these strains *Acinetobacter baumannii* (carbapenem-resistant), *Pseudomonas aeruginosa*, (carbapenem-resistant), *Enterobacteriaceae* (carbapenem-resistant), *Enterococcus faecium*, (vancomycin-resistant), *Staphylococcus aureus* (methicillin-resistant (SARM) and vancomycin-intermediate and resistant) represent the strains frequently encountered in hospital whose are responsible of hospital-acquired infection.

In this global context of the race to discover new antibacterial compounds, numerous ways have been investigated, such as antimicrobial peptides produced by mammals or insect² or chemically modified antimicrobial peptides³ or natural product from the marine world.⁴

Since the late 1990s, new natural marine brominated butenolides were isolated from ascidian or tunicates, representing the cadiolide family (Figure 1).⁵ The cadiolides (A-F), rearranged cadiolide I and hydroxylated cadiolide derivatives (G-H, J-M) have shown potential antibacterial activities on a large range of bacterial strains.⁶





Figure 1: natural cadiolides A-M

Since their discovery, few research groups have tackled their synthesis as well the synthesis of analogues. In 2005, Pouliot and Boukouvalas⁷ were the first to publish the synthesis of cadiolide B followed by us⁸ in 2013 with a one-step multicomponent strategy. In 2015, Boukouvalas reported an elegant step-economic strategy by Diels–Alder cycloaddition–cycloreversion towards these molecules.⁹ While using a multicomponent synthetic strategy, we have been able to obtain a large number of cadiolide analogues to study their structure-activity relationship,¹⁰ in particular by obtaining more or less brominated molecules or/and by introducing new functional groups like furoyl instead of benzoyl. Thus, some cadiolide analogues showed greater antibacterial activity than natural products with non-resistant gram positive or negative strains like *Bacillus cereus*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Bacillus subtilis*, *Salmonella typhi*, *Escherichia coli* and *Erwinia carotovora*. In some cases, the obtained activities were similar or better than broad-spectrum antibiotics such as tetracycline. This structure-activity relationship study also revealed that the phenolic hydroxyl group plays an important role and that the overall optimal bromine atom number is 3 to 4. Importantly, we showed that the substitution of a benzoyl group by a furoyl group allowed improving their

synthesized and evaluated other cadiolide analogues that showed activities in inhibiting bacterial biofilm formation.

Thus, in view of these promising results, we have decided to extend this structure-activity relationship study with resistant or not bacterial strains by varying the position of the furyl group around the furanonic skeleton, and by increasing the structural diversity with the introduction of new heterocyclic moieties such as thiophene and indole in replacement of the furyl group that we introduced earlier.¹⁰ Indeed, during a study of structure-activity relationship with heterocyclic chalcone analogues, Tran *et al.* have shown that the substitution of a furyl group by a thiophenyl or pyrridinyl group could bring, in some cases, an improvement of the antibacterial activity.¹² But, rather than pyridine we have preferred to introduce an indole group which is more easily functionalizable and can play an important role in antibacterial activity.¹³ Finally, we wanted to check if the central furanonic skeleton has a great importance on antibacterial activities and made the choice to convert the lactone ring into a lactam.



Scheme 1: Synthetic route to cadiolide derivatives

From suitable dioxinones, ketoalcohols and aldehydes (prepared according to reported procedure, Figure 2),^{8,10} more than ten cadiolide analogues were synthesized using our one-step multicomponent reaction (Scheme 1) including the family of furan **5a-c** (yields ranging from 18 to 28 %), thiophene **6a-d** (yields ranging from 25 to 96 %), indole **7a-b** (yields ranging from 6 to 9 %), lactam **8** (total yield 27 %, Z/E mixture: 55/45),¹⁴ and bis-furan **9a-b** (yields ranging from 16 to 88 %), cadiolide analogues (yield 16 %) (Table 1).




Figure 2 : list of dioxinones, ketoalcohols and aldehydes used


In order to have a point of comparison with our previously obtained results,⁹ we included in the evaluation of the antibacterial activities the cadiolide derivative **4** which had shown the best activities, and also synthesized for the first time the natural cadiolide D. In the present study, we have evaluated both the anti-bacterial activity of natural product cadiolide D and 13 new cadiolide analogues using both standard and antibiotic resistant-bacterial strains and, for the most active compounds, their cytotoxicity against keratinocyte cells.

Biological activity results

in vitro for their potential antibacterial activity against 4 Gram negative bacteria and 7 Gram positive bacteria. These bacteria have been chosen for their implications either in human health or in food-borne poisoning (see material and methods). No cadiolides have exhibited activity against Gram negative bacteria until 256 $\mu\text{g}\cdot\text{mL}^{-1}$ (Data not shown). In contrast, in the case of Gram positive bacteria, antibacterial activity has been observed against almost all target bacteria with MICs values between 2 and 256 $\mu\text{g}\cdot\text{mL}^{-1}$. The best activity is obtained with the indole derivatives **7a,b** with MICs of 2 $\mu\text{g}\cdot\text{mL}^{-1}$, below the reference compound **4** for most of the strains. When a phenol group is substituted by a furan group **5a-c**, the activity is greatly reduced with respect to the strains tested, more strongly for bis-furan analogues **9a,b**. On the other hand, when a phenol group is substituted by a thiophene **6a-d**, the activity becomes similar or even better than the

substituted group-activity relationship, when the furan group is in the methyldene position such as in **5c**, the activity observed is slightly reduced compared to furan derivatives **5a,b**. This effect is more strongly accentuated when it is a thiophene group which is in this same position such as in **6c** compared to the other positions of thiophen group **6a,b**. As underlined in our previous report,⁸ we can see an effect of the number of bromine atom on the activity by comparing the compounds **6c** and **6d**. Overall, we can pay particular attention to the influence of the phenol group substitution combined with the influence of a comparable number of bromine (i.e. **4**, **5c** and **7a**). Thus, we note that the substitution of the methyldene position by an indole group **7a** compensates for the negative effect of the decrease in the number of bromine atoms on the activity.

Table 1. Structures of synthesized cadiolide analogues and antibacterial activities of synthesized cadiolide analogues and cadiolide D. MIC results of three independent experiments ($\mu\text{g}\cdot\text{mL}^{-1}$). Bold numbers show the values obtained for the four most active compounds.



Analog	<i>B. cereus</i>	<i>B. subtilis</i>	<i>M. luteus</i>	<i>E. faecalis</i> NCTC 12697	<i>S. aureus</i> NCTC12493	<i>S. aureus</i> EMRSA-17	VRE
cadiolide D	32	64	64	64	32	64	64
4	8	16	8	16	8	8	32
5a	16	32	32	128	32	64	64
5b	16	16	16	32	32	64	64
5c	32	32	32	128	32	64	128
6a	4	8	8	32	8	16	32
6b	8	8	8	16	16	16	8
6c	64	32	128	64	32	256	32
6d	8	4	32	32	8	32	32
7a	2	4	2	16	2	8	8
7b	4	8	8	8	2	4	8
8	4	8	16	16	8	16	16
9a	128	256	256	256	64	128	256
9b	16	32	32	64	16	64	64
Gentamycin	0.25	0.25	0.25	8	0.5	>64	8
Vancomycin	1	0.5	≤0.13	4	1	2	>64

observed, comparable to the reference compound **4** thus opening the way towards the development of a new family of nitrogenated cardiolide derivative with a serious advantage of significant substitution variability on the nitrogen atom.

Furthermore, it is interesting to note that the indole derivatives **7a,b** are more potent against the two clinical resistant isolates tested (EMRSA-17 and VRE) than the compound **4** suggesting the absence of crossed resistance with cardiolide derivatives. N-methylated indole **7b** has similar activity than free indole **7a**, suggesting that further functionalization of cardiolide analogues via the indole position is possible without loss of activity.

The result of the antibacterial activity, described above has allowed us to select four compounds (i.e. **4**, **7a,b** and **8**) at a concentration of 160 $\mu\text{l.ml}^{-1}$ to evaluate their impact on cultured keratinocytes cells in order to identify any cytotoxic effect of these selected compounds. Since these compounds have been dissolved in DMSO, a same concentration (0.64 %) of DMSO needed for a good solubility has been used as a control (Cells + DMSO; Figure 3). We first observed that keratinocytes cells are sensitive to DMSO alone. Our result show that the three compounds **4**, **7a** and **7b** are devoid of cytotoxic activity against keratinocyte cells. In contrast, the compound **8**, used in the same condition, provoked an increase in term of cytotoxicity towards keratinocyte cells (55.7 ± 2.7 % of LDH release versus 23.7 ± 1.4 % of LDH release in control cells with DMSO). However, it is important to keep in mind, that cultured cells such as keratinocyte used in this study, are particularly sensitive, suggesting that it would be efficient, in the future, to test the toxicity of **8** against complex organisms such as the worm *Caenorhabditis elegans* or mice. In any case, our cytotoxic approach clearly demonstrated that **4**, **7a** and **7b** have no toxic activity towards keratinocyte cells.




Figure 3 : Cytotoxicity evaluation. Effect of **4**, **7a,b** and **8** cardiolides derivatives on LDH release by keratinocytes HaCaT cells after 24h of contact. Data are the mean of seven measurement from two independent experiment. Dotted line corresponded to the control condition (cells exposed to DMSO). Black bar represented the maximum of cells death (100 % of LDH release), NS : Not significantly different.

All together, our combined biological data (antibacterial activity and cytotoxicity) strongly suggest that the compounds **4**,

infection, while maintaining host cells integrity. It will be interesting in the future to modify slightly these compounds to obtain even more active molecules in particular by introducing a water-solubilizing function on the nitrogen atom of the indole group despite a higher cytotoxicity, the antibacterial activity of compound **8** is very encouraging and opens a way towards a new family of antibacterial molecules inspired by the cardiolide skeleton.

Acknowledgments

This work was funded by a national scholarship for study abroad PNE given by the Algerian ministry of higher education and scientific research to Sarra Bekri. This work was supported by Normandie Université, INSA Rouen, Université Rouen Normandie, CNRS and Labex SynOrg (ANR-11-LABX-0029). We are grateful to Albert Marcual (CNRS) for HRMS analyses. We wish to warmly thanks Professor Mathew Upton from the University of Plymouth for supporting MIC experiments.

Supplementary Material

Supplementary material of this article can be found online.

References and notes

- 27 February 2017; <https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed>
- R.E. Hancock, H.G. Sahl, *Nat. Biotechnol.* **2006**, 24, 1551–1557.
- C. de la Fuente-Núñez, F. Reffuveille, E. F. Haney, S. K. Straus, R. E. W. Hancock, *PLOS Pathogen*, **2014** May 22, 10(5), e1004152.
- A. R. Carroll, B. R. Copp, R. A. Davis, R. A. Keyzers, M. R. Prinsep, **2019**, 36 (1), 122-173.
- C. J. Smith, R. L. Hettich, J. Jompa, A. Tahir, M. V. Buchanan, C. M. Ireland, *J. Org. Chem.* **1998**, 63, 4147.
- a) T. H. Won, J.-E. Jeon, S.-H. Kim, S.-H. Lee, B. J. Rho, D.-C. Oh, K.-B. Oh, J. Shin, *J. Nat. Prod.* **2012**, 75, 2055 ; b) W. Wang, H. Kim, S.-J. Nam, B. J. Rho, H. Kang, *J. Nat. Prod.* **2012**, 75, 2049 ; c) C.-H. Ahn, T. H. Won, H. Kim, J. Shin, K.-B. Oh, *Bioorg. Med. Chem. Lett.* **2013**, 23, 4099 ; d) W. Wang, H. Kim, R. S. Patil, A. G. Giri, D. H. Won, D. Hahn, Y. Sung, J. Lee, H. Choi, S.-J. Nam, H. Kang, *Bioorg. Med. Chem. Lett.* **2017**, 27, 574.
- J. Boukouvalas and M. Pouliot, *Synlett*, **2005**, 343.
- P. A. Peixoto, A. Boulangé, S. Leleu and X. Franck, *Eur. J. Org. Chem.*, **2013**, 3316.
- J. Boukouvalas and C. Thibault, *J. Org. Chem.*, **2015**, 681.
- A. Boulangé, J. Parraga, A. Galán, N. Cabedo, S. Leleu, M. J. Sanz, D. Cortes and X. Franck, *Bioorg. Med. Chem.*, **2015**, 3618.
- S. Z. Mairink, L. C. A. Barbosa, J. Boukouvalas, S. H. S. P. Pedroso, S. G. Santos, P. P. Magalhães and L. M. Farias, *Med. Chem. Res.*, **2018**, 2426.
- T.-D. Tran, T.-T.-N. Nguyen, T.-H. Do, T.-N.-P. Huynh, C.-D. Tran and K.-M. Thai, *Molecules*, **2012**, 17, 6684.
- N. K. Kaushik, N. Kaushik, P. Attri, N. Kumar, C. H. Kim, A. K. Verma and E. H. Choi, *Molecules*, **2013**, 18, 6620.
- U. A. Pereira, T. A. Moreira, L. C. A. Barbosa, C. R. A. Maltha, I. S. Bomfim, S. S. Maranhão, M. O. Moreas, C. Pessoa and F. W. A. Barros-Nepomuceno, *Med. Chem. Commun.*, **2016**, 7, 345.